MAPT and Alzheimer disease: To further assess the potential links of MECP2 to the pathological changes typical for AD, the levels of soluble Aβ42 measured from temporal cortical samples as well as the levels of Aβ42, p-tau, and total-tau measured from CSF samples were correlated to the RNA, protein, and phosphorylation changes of MECP2 (Figure S1).